Lewis Score on Capsule Endoscopy as a Predictor of the Risk for Crohn’s Disease-Related Emergency Hospitalization and Clinical Relapse in Patients with Small Bowel Crohn’s Disease

Table 1

Baseline characteristics and concomitant treatment of the two groups, with and without additional treatment after initial CE.

Treatment change		Yes	No
		Gender (no. of patients) (%)
Male		62 (72.1)	28 (71.8)
Female		24 (27.9)	11 (28.2)
Age (years)	Median (range)	38.5 (14–80)	37 (14–67)
Disease duration (years)	Median (range)	9 (0–43)	9 (0–26)
Disease type (no. of patients) (%)
Ileitis type		46 (53.5)	20 (51.3)
Ileocolonic type		40 (46.5)	19 (48.7)
Previous surgery (no. of patients) (%)
None		29 (33.7)	19 (48.7)
>1		57 (66.3)	20 (51.3)
Perianal lesion (no. of patients) (%)
None		49 (57.0)	19 (48.7)
Yes		37 (43.0)	20 (51.3)
Indications for CE (no. of patients) (%)
Symptom		21 (24.4)	11 (28.2)
Monitoring		65 (75.6)	28 (71.8)
CDAI	Mean (SD)	94.4 (55.6)	123.1 (86.6)
Serum albumin level (g/dl)	Mean (SD)	4.2 (0.4)	3.7 (0.7)
Serum CRP level (mg/dl)	Mean (SD)	0.19 (0.4)	0.87 (1.9)
Lewis score	Median (range)	135 (0–4128)	450 (0–3922)
Stenosis score	0	79	27
	196–400	6	5
	2352–	1	7
Medications (no. of patients) (%)
5ASA		77 (89.5)	34 (87.2)
Elemental diet		49 (57.0)	29 (74.4)
Immunomodulator		16 (18.6)	9 (23.1)
Anti-TNF agent		61 (70.9)	25 (64.1)

CDAI: Crohn’s disease activity index; CRP: C-reactive protein.